Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
-
Notice Type:
Contract Notice
Published Date:
20 November 2019
Closing Date:
02 December 2019
Location(s):
PL229 Gliwicki (PL Poland/POLSKA)
Description:
Successive drug delivery for the Oncology Center - Institute of Maria Skłodowska-Curie branch in Gliwice

1. The subject of this contract is the gradual delivery of medicines for the Oncology Center - Institute of Maria Skłodowska-Curie Branch in Gliwice, hereinafter referred to as the Employer.

2. A detailed description of the subject of the contract is included in the assortment and price specification constituting Annex 2.1-2.2 to the ToR and the contract template constituting Annex 4 to the ToR.

3. If the medicine in the international name is on the reimbursement list, then the medicine offered must appear on it and its price must be equal to or lower than the funding limits.

4. The Awarding Entity does not envisage concluding a framework agreement, establishing a dynamic purchasing system, electronic auction and supplementary orders.

5. Detailed information on these proceedings is contained in the ToR.


Trastuzumab emtansine

Task # 1 - Trastuzumab emtansine

A detailed description of the subject of the contract is included in the assortment and price specification constituting Annex 2.1 to the ToR and the contract template constituting Annex 4 to the ToR.

The medicinal products subject to this order have established quality standards. These standards were established for each medicinal product during its registration and are the same for the chemical substances they contain. Medicinal products for their use do not require any distinctive elements within the individual substances. In addition, every medicinal product that is traded in Poland must be registered.

Medicinal products that are the subject of the order must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. for marketing in the Republic of Poland for the offered medicinal product and to present them at the request of the Purchaser.

Preparations with the same chemical name, but with different doses, must be offered from one manufacturer, so that in practice it is possible to combine doses.

If no dose size is given, the Purchaser reserves the right to place orders for all doses produced by a given manufacturer.

If the medicinal product in the international name is on the reimbursement list, then the offered medicinal product must be on it and its price must be equal to or lower than the funding limits.

The medicinal products on offer must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with an expiry date shorter than 12 months only if the Contractor obtains the written consent of the Employer.


Trifluridine with Tipiracil

Task # 2 - Trifluridine from Tipiracil

A detailed description of the subject of the contract is contained in the product and price specification constituting Annex 2.2 to the ToR and the contract template constituting Annex 4 to the ToR.

The medicinal products subject to this order have established quality standards. These standards were established for each medicinal product during its registration and are the same for the chemical substances they contain. Medicinal products for their use do not require any distinctive elements within the individual substances. In addition, every medicinal product that is traded in Poland must be registered.

Medicinal products that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. for marketing in the territory of the Republic of Poland for the offered medicinal product and to present them at the request of the Employer.

Preparations with the same chemical name, but with different doses, must be offered from one manufacturer, so that in practice it is possible to combine doses.

If no dose size is given, the Purchaser reserves the right to place orders for all doses produced by a given manufacturer.

If the medicinal product in the international name is on the reimbursement list, then the offered medicinal product must be on it and its price must be equal to or lower than the funding limits.

The medicinal products on offer must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with an expiry date shorter than 12 months only if the Contractor obtains the written consent of the Employer.

Download full details as .pdf
The Buyer:
Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach
CPV Code(s):
33600000 - Pharmaceutical products